San Diego’s Illumina Inc. (Nasdaq: ILMN) has entered into a series of separate agreements for its non-invasive pre-natal testing products to be used in Europe. Illumina’s tests will be used by the Center for Human Genetics and Laboratory Diagnostics in Germany, the Genoma Group in Italy and Biomnis Laboratories in France.
“Biomnis evaluated the different technologies and selected Illumina because of their high level of performance as published in respected, peer-reviewed medical journals,” said Biomnis CEO Charles Woler.
In morning trading on Monday, Illumina stock rose more than 3.7 percent. The stock analysis firm Trade-Ideas LLC identified Illumina (ILMN) as a “momo momentum candidate” for its recent stock rises.
9885 Towne Centre Dr.
San Diego, CA 92121